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Abstract
Background: Cells from individuals with Friedreich’s ataxia (FRDA) show reduced activities of antioxidant enzymes and
cannot up-regulate their expression when exposed to oxidative stress. This blunted antioxidant response may play a central
role in the pathogenesis. We previously reported that Peroxisome Proliferator Activated Receptor Gamma (PPARc)
Coactivator 1-alpha (PGC-1a), a transcriptional master regulator of mitochondrial biogenesis and antioxidant responses, is
down-regulated in most cell types from FRDA patients and animal models.
Methodology/Principal Findings: We used primary fibroblasts from FRDA patients and the knock in-knock out animal
model for the disease (KIKO mouse) to determine basal superoxide dismutase 2 (SOD2) levels and the response to oxidative
stress induced by the addition of hydrogen peroxide. We measured the same parameters after pharmacological stimulation
of PGC-1a. Compared to control cells, PGC-1a and SOD2 levels were decreased in FRDA cells and did not change after
addition of hydrogen peroxide. PGC-1a direct silencing with siRNA in control fibroblasts led to a similar loss of SOD2
response to oxidative stress as observed in FRDA fibroblasts. PGC-1a activation with the PPARc agonist (Pioglitazone) or
with a cAMP-dependent protein kinase (AMPK) agonist (AICAR) restored normal SOD2 induction. Treatment of the KIKO
mice with Pioglitazone significantly up-regulates SOD2 in cerebellum and spinal cord.
Conclusions/Significance: PGC-1a down-regulation is likely to contribute to the blunted antioxidant response observed in
cells from FRDA patients. This response can be restored by AMPK and PPARc agonists, suggesting a potential therapeutic
approach for FRDA.
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Introduction
Friedreich’s ataxia (FRDA) is an autosomal recessive inherited
disorder affecting approximately 1 in every 40 000 individuals [1]
in Western Europe. It is characterized by progressive gait and limb
ataxia, dysarthria, areflexia, loss of vibratory and position sense,
and progressive weakness of central origin. Additional features
include scoliosis, high risk of diabetes [2–6] and a hypertrophic
cardiomyopathy that can cause premature death [3,4,7]. Age of
onset is usually in childhood or adolescence, but it may vary from
infancy to adulthood.
A large GAA repeat expansion in the first intron of the FXN
gene is the most common mutation underlying FRDA [8]. Patients
are homozygous for this mutation, or, rarely, are compound
heterozygotes for the GAA repeat expansion and a different FXN
loss-of-function mutation. They show severely reduced levels of the
FXN-encoded mitochondrial protein frataxin, a highly conserved
protein with homologs in all eukaryotes and in Gram-negative
bacteria [8]. FXN down-regulation has been linked to the property
of long GAA repeats to adopt a triple helical structure that directly
impedes transcription in vitro [9,10]. In the nucleus of cells from
human patients and mouse models, FXN silencing is associated
with epigenetic marks of transcription repressive heterochromatin
near expanded GAA repeats [11,12]. Whether the triplex forming
ability of GAA repeats is involved in this chromatin remodeling
process is unknown.
Frataxin is an essential protein in higher organisms, as first
revealed by the embryonic lethality of fxn gene knockout in the
mouse [13]. Yeast cells can instead survive without frataxin, but
they progressively lose mitochondrial function and mitochondrial
DNA [14].
The function of frataxin has not yet been completely elucidated,
but its involvement in mitochondrial iron metabolism is supported
by current literature. Frataxin has a compact globular structure
with functionally important surface features, in particular a
negatively charged ridge that binds ferrous iron with low affinity
[15,16]. Under conditions of iron excess, frataxin has been
reported to show ferroxidase activity and form high molecular
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10025weight complexes containing a ferric iron core [17]. This property,
which has been proposed to be important for iron detoxification in
the mitochondrial compartment, is most evident for the yeast
frataxin homolog yfh1. The functional role of these iron-
containing frataxin polymers, as well as of frataxin oligomers
reported to form at lower iron concentration, is still controversial
[18,19]. Multiple abnormalities of iron metabolism occur when
frataxin levels are insufficient: decreased activities of iron-sulfur
cluster (ISC) containing proteins [20], accumulation of iron in
mitochondria and depletion in the cytosol [21], enhanced cellular
iron uptake [22,23], and, in some models, reduced heme synthesis
[24,25]. These abnormalities point to a defective utilization of iron
for biosynthetic processes taking place in the mitochondria, in
particular ISC synthesis. ISCs are prosthetic groups for several
mitochondrial and extra-mitochondrial enzymes, involved in
energy metabolism (aconitase and complexes I, II and III of the
respiratory chain), iron metabolism (iron-responsive protein 1,
IRP1, and ferrochelatase), purine metabolism (xanthine oxidase)
and DNA repair [26]. Accumulation of iron in the mitochondria
with increased cellular uptake and cytosolic depletion occurs when
ISC synthesis is defective, suggesting a role of frataxin in this
process. Current evidence supports a direct interaction of frataxin
with components of the mitochondrial ISC synthesis machinery,
but a non-essential role in the process [27].
Evidence of oxidative stress has been found in most, though not
all models of frataxin deficiency [28–35]. In FRDA patients,
increased plasma levels of malonyldialdehyde (a lipid peroxidation
product) [34], increased urinary 8-hydroxy-2’-deoxyguanosine (a
marker of oxidative DNA damage) [35], decreased plasma free
glutathione, and increased plasma glutathione S-transferase
activity [29] indicate an oxidative stress condition. Oxidative
stress is thought to derive from the strong reactivity of the excess
mitochondrial iron with reactive oxygen species (ROS) present in
that compartment, including the Fenton reaction that generates
the highly toxic hydroxyl radical. Accordingly, yfh1-deficient yeast
[14] and cells from FRDA patients [36] are highly sensitive to
oxidants such as hydrogen peroxide H2O2. Respiratory chain
dysfunction caused by decreased activity of the ISC-containing
complexes I, II and III is likely to further aggravate oxidative stress
by increasing leakage of electrons and formation of superoxide.
Frataxin deficient cells not only generate more free radicals,
they also show a reduced ability to mobilize antioxidant defenses,
in particular to induce SOD2 expression following exposure to
oxidants such as H2O2 and iron [31]. The mechanism underlying
this defect has not yet been understood. Its investigation has
prompted the present study.
In a previous study we have shown reduced expression of the
peroxisome proliferator activated receptor gamma (PPAR-c)
coactivator 1a (PGC-1a) in several tissues from frataxin-deficient
mice, with the notable exception of the heart. We have observed
PGC-1a down-regulation also in neural precursor cells from the
subventricular zone of these animals, and in fibroblasts and
lymphoblastoid cell lines from FRDA patients [37,38]. PGC-1a is
a multifunctional protein found at higher levels in tissues with high
metabolic requirement such as brown fat, skeletal muscle, kidney,
heart, and brain [39–41], that functions as a coactivator to most
nuclear receptors and to several other transcription factors [42]. It
is a critical regulator that links metabolic activity to relevant
environmental stimuli in multiple pathways, including those
responsible for adipogenesis, gluconeogenesis, myogenesis, and
mitogenesis [43]. PGC-1a has also emerged as a key factor in the
induction of many antioxidant programs in response to oxidative
stress, both in vivo and in vitro [44–47], in particular in neurons
[46]. RNAi knockdown of Pgc1a prevents the induction by ROS of
antioxidant enzymes such as superoxide dismutase 1 (Sod1),
superoxide dismutase 2 (Sod2), and Gpx1, as well as the uncoupling
proteins Ucp1 and Ucp2 [46], indicating that it mediates these
protective responses [46,47].
We further observed that in C2C12 myoblasts, but not in
cardiomyocytes, PGC-1a and a reporter gene under the control of
the PGC-1a promoter are rapidly down-regulated when frataxin
expression is inhibited by an shRNA [37], indicating that some
mechanism directly links an early effect of frataxin deficiency with
reduced PGC-1a transcription in this cell type, and presumably in
other cells that also down-regulate PGC-1a when frataxin levels
are low.
In this study we tested whether the PGC-1a down-regulation
occurring in FRDA cells could be in part responsible for the
blunted antioxidant response observed in frataxin-deficiency. Our
results support this hypothesis, indicating a possible therapeutic
target in FRDA.
Results
PGC-1a reduction is associated to reduced SOD2 in FRDA
fibroblasts and does not increase after H2O2 incubation
The baseline expression levels of SOD2 and PGC-1a were
reduced in fibroblasts from FRDA patients when compared to
healthy controls cells (Fig. 1A). Treatment with 100 mMH 2O2 for
48 and 72 hours increased both SOD2 and PGC-1a mRNA and
protein in control cells, but not in FRDA fibroblasts (Fig. 1B–D).
Incubation with H2O2 of SKNBE neuroblastoma cells was also
accompanied by PGC-1a and SOD2 induction at both mRNA
and protein level, showing that this response is not specific for
fibroblasts (Fig. 1E–G).
PGC-1a down-regulation by RNAi results in lack of SOD2
response to H2O2
Incubation of fibroblasts from healthy and FRDA subjects for
72 hours with a PGC-1a specific siRNA significantly decreases
mRNA and protein levels when compared to cells transfected
with a control non-specific siR N A ,a ss h o w ni nf i g u r e2 A – C .I n
these conditions, SOD2 mRNA and protein reduction was
significant both in control and FRDA fibroblasts. These data are
in agreement with reports indicating that PGC-1a controls
SOD2 expression [47,48,49]. We also confirmed our previous
finding [37] that PGC-1a silencing results in frataxin down-
regulation.
Effect of PPARc and AMPK agonists on the antioxidant
response in FRDA fibroblasts
We tested whether drugs known to up-regulate PGC-1a could
restore SOD2 induction by H2O2 in FRDA cells. PPARc and the
AMP-dependent protein kinase (AMPK) are major inducers of
PGC-1a activity and expression [50–54].
In a first set of experiments we evaluated the effect of the
PPARc agonist Pioglitazone. We had previously shown that a
different potent PPARc agonist, Azelaoyl-PAF, was able to
increase PGC-1a and frataxin expression in FRDA and control
fibroblasts [55]. Pioglitazone at a concentration of 10 mM was able
to increase PGC-1a mRNA and protein levels after 72 and
96 hours of incubation of both control and FRDA fibroblasts, as
shown in Fig. 3A–C. In the same conditions, SOD2 levels were
also increased, with a more robust effect in FRDA cells. Frataxin
expression showed a non-significant trend toward up-regulation in
this set of experiments (Fig. 3A–C). Interestingly, in SKNBE
neuroblastoma cells, Pioglitazone incubation for 96 hours at
PGC1a and Antioxidants in FRDA
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amount (Fig. 3D–F).
We then exposed cells to the AMPK agonist AICAR, showing
that this molecule at a concentration of 2 mM, strongly up-
regulates PGC-1a and SOD2 in both healthy controls and FRDA
fibroblasts after 48 hours of incubation (Fig. 4A–C).
Accordingly, Pioglitazone 10 mM or AICAR 2 mM, incubation
for 5 hours with a following addiction of 100 mMH 2O2 for
Figure 1. SOD2 and PGC-1a expression in FRDA fibroblasts and H2O2 treatments. A. Quantitative Real-Time PCR analysis: FXN (Blue bars),
PGC-1a (Red bars) and SOD2 (Green bars) mRNA quantification in primary fibroblasts from healthy controls and FRDA patients. B. Quantitative Real-
Time PCR analysis: FXN (Blue bars), PGC-1a (Red bars) and SOD2 (Green bars) mRNA quantification in primary fibroblasts from healthy controls and
FRDA patients after incubation with 100 mMH 2O2 at 48 and 72 hours. C. Western Blot analysis: b-Actin (Act), PGC-1a (PGC-1), frataxin (FXN),
mitochondrial superoxide dismutase (SOD2) protein in primary fibroblasts from healthy controls and FRDA patients after incubation with 100 mM
H2O2 at 48 and 72 hours. D. Densitometric scan analysis of five independent Western blots from healthy controls and FRDA patients after incubation
with 100 mMH 2O2 at 48 and 72 hours: FXN (Blue bars), PGC-1a (Red bars) and SOD2 (Green bars). The relative intensities of the bands were quantified
using the Image J Software, and all the values were normalized to the intensities of the respective b-Actin signal. E. Quantitative Real-Time PCR
analysis: FXN (Blue bars), PGC-1a (Red bars) and SOD2 (Green bars) mRNA quantification in SKNBE neuroblastoma cells after incubation with 100 mM
H2O2 at 48 and 72 hours. F. Western Blot analysis: b-Actin (Act), PGC-1a (PGC-1), frataxin (FXN), mitochondrial superoxide dismutase (SOD2) protein in
SKNBE neuroblastoma cells after incubation with 100 mMH 2O2 at 48 and 72 hours. G. Densitometric scan analysis of five independent Western blots
from SKNBE cells after incubation with 100 mMH 2O2 at 48 and 72 hours: FXN (Blue bars), PGC-1a (Red bars) and SOD2 (Green bars). The relative
intensities of the bands were quantified using the Image J Software, and all the values were normalized to the intensities of the respective b-Actin
signal. Results are expressed as a fold increase of the means (mean 6 SEM) over the value of expression in the respective untreated control cells
arbitrarily set as 1. (n=5, ***p,0.001, **p,0.01,*p,0.05; Mean +/2 SEM) for all the experiments.
doi:10.1371/journal.pone.0010025.g001
Figure 2. PGC-1a downregulation by a specific RNAi. A. Quantitative Real-Time PCR analysis: FXN (Blue bars), PGC-1a (Red bars) and SOD2
(Green bars) mRNA quantification in primary fibroblasts from healthy controls and FRDA patients after 72 hours transfection with a PGC-1a specific
siRNA, as control a fluoresceine-conjugated siRNA was used. B. Western Blot analysis: b-Actin (Act), PGC-1a (PGC-1), frataxin (FXN), mitochondrial
superoxide dismutase (SOD2) protein in primary fibroblasts from healthy controls and FRDA patients after 72 hours transfection with a PGC-1a
specific siRNA, as control a fluoresceine-conjugated siRNA was used. C. Densitometric scan analysis of five independent Western blots from healthy
controls and FRDA patients after 72 hours transfection with a PGC-1a specific siRNA, as control a fluoresceine-conjugated siRNA was used: FXN (Blue
bars), PGC-1a (Red bars) and SOD2 (Green bars). The relative intensities of the bands were quantified using the Image J Software, and all the values
were normalized to the intensities of the respective b-Actin signal. (n=5, ***p,0.001, **p,0.01, *p,0.05; Mean +/2 SEM) for all the experiments.
doi:10.1371/journal.pone.0010025.g002
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F). In these conditions, an increase in PGC-1a levels was also
observed when compared to treatment with H2O2 alone (Fig. 4D–
F).
Effect of Pioglitazone in vivo in frataxin-deficient (KIKO)
mice
Based on in vitro results, we tested the effect of Pioglitazone on
the levels of PGC-1a, SOD2 and frataxin in frataxin-deficient
mice. For these experiments, we used the fxn
(GAA)230/2 (KIKO)
mice that express 25–35% of wild-type frataxin levels, but have no
detectable motor abnormality of pathological change. Ten KIKO
mice received Pioglitazone (25 mg/Kg/day) via oral administra-
tion for one month. No change was observed in the body weight of
the mice (data not shown). In the spinal cord, a primary affected
tissue in the disease, no effect was observed on frataxin expression,
while Pgc-1a and Sod2 levels were slightly increased (Fig. 5A–D).
In the cerebellum, Pgc-1a and Sod2 levels were significantly
increased (Fig. 5B–D). No effect was observed on frataxin
expression. Surprisingly, in a group of 10 wt mice no effect was
observed after Pioglitazone administration.
Discussion
Our results provide a link between the previous independent
observations of a blunted antioxidant response in cells from FRDA
patients [31,32] and the PGC-1a down-regulation occurring in
most cell types with frataxin deficiency [37]. These phenomena
Figure 3. Effect of Pioglitazone on the antioxidant response in FRDA fibroblasts and SKNBE neuroblastoma cells. A. Quantitative Real-
Time PCR analysis: FXN (Blue bars), PGC-1a (Red bars) and SOD2 (Green bars) mRNA quantification in primary fibroblasts from healthy controls and
FRDA patients after incubation with 10 mM Pioglitazone at 24, 48, 72 and 96 hours. B. Western Blot analysis: b-Actin (Act), PGC-1a (PGC-1), frataxin
(FXN), mitochondrial superoxide dismutase (SOD2) protein in primary fibroblasts from healthy controls and FRDA patients after incubation with
10 mM Pioglitazone at 72 and 96 hours. C. Densitometric scan analysis of five independent Western blots from healthy controls and FRDA patients
after incubation with 10 mM Pioglitazone at 72 and 96 hours: FXN (Blue bars), PGC-1a (Red bars) and SOD2 (Green bars). The relative intensities of the
bands were quantified using the Image J Software, and all the values were normalized to the intensities of the respective b-Actin signal. D.
Quantitative Real-Time PCR analysis: FXN (Blue bars), PGC-1a (Red bars) and SOD2 (Green bars) mRNA quantification in SKNBE neuroblastoma cells
after incubation with 10 mM Pioglitazone at 72 and 96 hours. E. Western Blot analysis: b-Actin (Act), PGC-1a (PGC-1), frataxin (FXN), mitochondrial
superoxide dismutase (SOD2) protein in SKNBE neuroblastoma cells after incubation with 10 mM Pioglitazone at 72 and 96 hours. F. Densitometric
scan analysis of five independent Western blots from SKNBE cells after incubation with 10 mM Pioglitazone at 72 and 96 hours: FXN (Blue bars), PGC-
1a (Red bars) and SOD2 (Green bars). The relative intensities of the bands were quantified using the Image J Software, and all the values were
normalized to the intensities of the respective b-Actin signal. (n=5, ***p,0.001, **p,0.01,*p,0.05; Mean +/2 SEM) for all the experiments.
doi:10.1371/journal.pone.0010025.g003
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possible therapeutic targets.
Oxidative stress has been considered a major pathogenic
mechanism in FRDA, even though the data are in same case
controversial. Previous studies [56,57] found no evidence of
oxidative stress in the target tissues of conditional knockout mouse
models (heart and nervous system), which nevertheless develop
FRDA-like pathology and show the typical biochemical defects of
FRDA, including multiple ISC enzyme deficiencies and, in late
stages, gross mitochondrial iron accumulation. One possible
explanation could be that the total absence of frataxin, as found
in targeted cells in conditional knock-outs, leads to an almost
Figure 4. Effect of AICAR on the antioxidant response in FRDA fibroblasts and SKNBE neuroblastoma cells. A. Quantitative Real-Time
PCR analysis: FXN (Blue bars), PGC-1a (Red bars) and SOD2 (Green bars) mRNA quantification in primary fibroblasts from healthy controls and FRDA
patients after incubation with 2 mM AICAR at 48 hours. B. Western Blot analysis: b-Actin (Act), PGC-1a (PGC-1), frataxin (FXN), mitochondrial
superoxide dismutase (SOD2) protein in primary fibroblasts from healthy controls and FRDA patients after incubation with 2 mM AICAR at 48 hours.
C. Densitometric scan analysis of five independent Western blots from healthy controls and FRDA patients after incubation with 2 mM AICAR at
48 hours: FXN (Blue bars), PGC-1a (Red bars) and SOD2 (Green bars). The relative intensities of the bands were quantified using the Image J Software,
and all the values were normalized to the intensities of the respective b-Actin signal. D. Quantitative Real-Time PCR analysis: FXN (Blue bars), PGC-1a
(Red bars) and SOD2 (Green bars) mRNA quantification in primary fibroblasts from FRDA patients after incubation with 100 mMH 2O2 alone or in
combination with 10 mM Pioglitazone or 2 mM AICAR for 72 hours. E. Western Blot analysis: b-Actin (Act), PGC-1a (PGC-1), frataxin (FXN),
mitochondrial superoxide dismutase (SOD2) protein in primary fibroblasts from FRDA patients after incubation with 100 mMH 2O2 alone or in
combination with 10 mM Pioglitazone or 2 mM AICAR for 72 hours. F. Densitometric scan analysis of five independent Western blots from SKNBE
cells after incubation with 100 mMH 2O2 alone or in combination with 10 mM Pioglitazone or 2 mM AICAR for 72 hours: FXN (Blue bars), PGC-1a (Red
bars) and SOD2 (Green bars). The relative intensities of the bands were quantified using the Image J Software, and all the values were normalized to
the intensities of the respective b-Actin signal. (n=5, ***p,0.001, **p,0.01, *p,0.05; Mean +/2 SEM) for all the experiments.
doi:10.1371/journal.pone.0010025.g004
Figure 5. In vivo Pioglitazone administration in KIKO mice. A. Quantitative Real-Time PCR analysis: fxn (Blue bars), pgc-1a (Red bars) and sod2
(Green bars) mRNA quantification in the spinal cord of the KIKO mice after receiving oral administration of Pioglitazone 25 mg/Kg/day for one month.
B. Quantitative Real-Time PCR analysis: fxn (Blue bars), pgc-1a (Red bars) and sod2 (Green bars) mRNA quantification in the cerebellum of the KIKO
mice after receiving oral administration of Pioglitazone 25 mg/Kg/day for one month. C. Western Blot analysis: b-actin (Act), pgc-1a (PGC-1), frataxin
(FXN), mitochondrial superoxide dismutase (sod2) protein in the spinal cord and cerebellum of the KIKO mice after receiving oral administration of
Pioglitazone 25 mg/Kg/day for one month. D. Densitometric scan analysis of five independent Western blots from the spinal cord and cerebellum of
the KIKO mice after receiving oral administration of Pioglitazone 25 mg/Kg/day for one month: FXN (Blue bars), PGC-1a (Red bars) and SOD2 (Green
bars). The relative intensities of the bands were quantified using the Image J Software, and all the values were normalized to the intensities of the
respective b-Actin signal. (n=10, **p,0.01,*p,0.05; Mean +/2 SEM) for all the experiments.
doi:10.1371/journal.pone.0010025.g005
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generated. Indeed, in yeasts studies evidence of oxidative damage
rapidly follows frataxin silencing before the loss of mitochondrial
function [58]. The respiratory chain, though impaired, remains
partially functional in FRDA target tissues and in animal models
with reduced frataxin levels, as well as in cell models with partial
frataxin deficiency or expressing a mutated frataxin protein
[59,60]. Accordingly, studies in these systems [59,61,62], including
tissue samples from FRDA patients, have shown evidence of
chronic oxidative stress, and oxidative stress markers have been
found in the blood [29,34] and urine [35] of FRDA patients. In
the case of the fibroblasts utilized in the present study, we obtained
further evidence of increased ROS production by revealing higher
levels of superoxide than in control fibroblasts (Methods S1 and
Fig. S1). Then, we confirmed [31,32] that exposure of FRDA
fibroblasts to moderate oxidative stress, as induced by exogenously
added H2O2 or iron, or by partial respiratory chain inhibition, fails
to up-regulate antioxidant enzymes. Only strong stressors, like
very high iron or H2O2 concentration in the medium have shown
to possibly up-regulate SOD2 in FRDA fibroblasts [31] by
triggering NFkB signaling. These data indicate the failure of a
response mechanisms dealing with the control of lower, chronic
levels of oxidative stress. With reference to pathogenesis, it is
conceivable that, while this deficient response does not appear to
be harmful to unaffected cells in FRDA like fibroblasts, unless they
are exposed to additional oxidative stress, it may be deleterious for
vulnerable cell types, such as neurons even in basal conditions.
The observed failure to induce antioxidant defenses contrasts
with the expected homeostatic response. Several pathways are
physiologically activated by ROS, leading to increased levels and
activity of antioxidant enzymes and to mitochondrial biogenesis
[42–44,46,47,63,64]. Key factors for antioxidant enzyme induc-
tion are nuclear factor-E2-related factor-2 (Nrf2), a transcription
factor that serves as a cellular sensor for oxidative stress [64,65],
and PGC-1a [66].
PGC-1a is also a key player in the ROS-induced mitochondrial
biogenesis, along with the transcription factor nuclear respiratory
factor-1 (NRF-1) and the mitochondrial transcription factor Tfam
[48,66–71].
A recent study suggested that impaired nuclear translocation of
Nrf2 may underlay the lack of oxidative stress response in FRDA
cells [71]. Though this mechanism may play a role, Nrf2-regulated
genes primarily include heme oxygenase-1 (HO-1), NAD(P)H:-
quinone oxidoreductase-1 (NQO1), glutathione S-transferases,
and the glutathione-synthesizing enzymes glutamate-cysteine
ligase catalytic subunit (GCLC) and glutamate-cysteine ligase
modifier subunit (GCLM), while PGC-1a may be more relevant
for SOD2 induction.
The importance of PGC-1a in these metabolic programs was
further revealed through the generation of PGC-1a null mice.
These mice display a reduced basal expression of many
mitochondrial genes in liver, brain, skeletal muscle, and heart
compared with wild-type (WT) animals [72–74]. Furthermore,
PGC-1a knockout (KO) mice underlying PGC-1a as an important
factor in brain structure and function. PGC-1a KO animals
present neurodegenerative lesions in the striatum, as well as
behavioral abnormalities [74]. These lesions present characteristic
similar to those observed in many models with altered ROS levels.
Thus, PGC-1a could play an important role in ROS control. The
precise role of PGC-1a in ROS metabolism is still undiscovered.
Several groups have reported that the expression of mitochondrial
ROS-detoxifying enzymes increases with PGC-1a [75–77].
Conversely, muscle from PGC-1a knockout mice shows a mild
reduction of SOD2 [78]. Interestingly, PGC-1a direct down-
regulation by RNAi results in the downregulation of SOD2 and
other antioxidant enzymes, and particularly generates a lack of
their induction after exposure to stressors such as H2O2, markedly
resembling the situation in frataxin-deficient cells [46]. This
important finding, together with our previous observation that
frataxin deficiency leads to reduced levels of PGC-1a and its target
genes in most investigated cell types prompted us to study whether
PGC-1a could be involved in the blunted antioxidant response in
FRDA.
We show that lack of PGC-1a induction parallels the lack of
SOD2 induction in FRDA fibroblasts exposed to H2O2,t h a t
PGC-1a silencing by siRNA in normal fibroblasts mimics the lack
of antioxidant response found in FRDA cells, and that
pharmacological PGC-1a up-regulation obtained by stimulating
its activators PPARc or AMPK can restore the SOD2 response in
H2O2 stressed FRDA cells. In addition, we show that in vivo
treatment of KIKO mice with the PPARc agonist Pioglitazone,
known to cross the blood-brain barrier, increased SOD2 levels
both in the spinal cords and cerebellum. Those tissues are
primary affected in patients. Taken together, these results raise
the hypothesis that the PGC-1a repression observed in FRDA
cells could underlie the lack of antioxidant response. We also
show that two pathways that can induce PGC-1a remain
functional and can be stimulated in order to stimulate a down-
stream response.
Similar results were obtained in a study on an animal model of a
mitochondrial disorder, a skeletal muscle conditional knock-out
mouse for the gene encoding the cytochrome c oxidase assembly
factor COX10. In that model as well, mitochondrial biogenesis
and antioxidant responses were not effectively induced unless the
PPARc/PGC-1a pathway was genetically or pharmacologically
stimulated [78].
In our experiments, AMPK kinase stimulation resulted in a
faster up-regulation of PGC-1a and SOD2 than the PPARc
agonist, but in both cases their levels became close to those in
control cells. A possible explanation is that in FRDA cells, in
addition to be transcriptionally down-regulated, PGC-1a is also
mostly present in a less functional form, possibly due to acetylation
and lack of AMPK phosphorylation. Activation of the AMPK
pathway would then result in the direct activation of the existing
PGC-1a pool by phosphorylation and SIRT1-mediated deacetyla-
tion [79,80], leading to rapidly increased transcription of target
genes, including PGC-1a itself. PPARc stimulation would have
instead to first recruit the smaller active PGC-1a pool to co-
stimulate transcription of a first set of target genes, again including
PGC-1a itself, whose progressively higher abundance would later
amplify the response. Together with our previous findings that
after frataxin silencing with an shRNA in cultured myoblasts,
PGC-1a is rapidly repressed and a reporter gene driven by a PGC-
1a promoter is also rapidly down-regulated [37], these data
suggest that frataxin deficiency directly leads to PGC-1a
inactivation, followed by decreased transcription. AMPK, which
is a target of ROS and the main activator of PGC-1a, appears an
appealing candidate as the responsible for these events, but direct
evidence is still lacking.
Materials and Methods
Ethics statement
Patients and healthy controls were enrolled on a voluntary basis
at the ‘‘Federico II’’ University in Naples, Italy. Written informed
consent to participate in the study and provide a skin biopsy was
obtained according to a protocol approved by the ‘‘Federico II’’
ethics committee.
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The study included five FRDA patients from the department of
Neurology ‘‘Federico II’’ Naples, and five unrelated healthy
controls. Patients were homozygous for GAA repeat expansions
between 500 and 1,200 repeats, with an age of onset for the
disease ranging between 20 and 30 years old. All enrolled patients
started treatment with Idebenone 5 mg/kg after the skin biopsies
were obtained. They were also following a standard protocol of
physiotherapy.
Cell cultures
Fibroblast primary cell cultures were obtained from skin
biopsies of FRDA patients and healthy controls. Human
neuroblastoma derived cells (SKNBE) are commercially available
(in Europe from ATCC-LGC Standards, line number CRL-2271).
Primary fibroblasts and SKNBE cells were grown in DMEM
supplemented with 15% fetal bovine serum (FBS), 2 mM L-
glutamine, 100 U/ml penicillin and streptomycin (P/S). All
experiments with fibroblasts were conducted between fourth and
eleventh passages.
Cell Treatment
Primary fibroblasts and SKNBE cells were incubated for 48 and
72 hours in presence of 100 mMH 2O2 (Sigma Aldrich) or DMEM
alone as control before total RNA and protein extraction. 10 mM
Pioglitazone (AD-4833, Takeda pharmaceuticals) and 2 mM 5-
Aminoimidazole-4-carboxamide 1-b-D-ribofuranoside (AICAR,
Sigma Aldrich) were used for in vitro experiments.
Animal experiments
20 (C57BL6/j; fxnGAA
230/2) KIKO mice eight months old
were used for in vivo experiments. Precisely, 10 KIKO mice
received 25 mg/Kg/day of Pioglitazone/0.1% carboxymethylcel-
lulose sodium salt (Sigma Aldrich) via oral administration (gavages)
for 1 month. A control group of 10 KIKO mice received 0.1%
carboxymethylcellulose sodium salt. Mice body weight was daily
monitored. Mice were then sacrificed via a cervical dislocation and
tissues were extracted for the analysis. All animal procedures
respected regulations and guidelines of the Belgian state and
European Union and were approved by the animal ethics and
welfare committee of the Universite ´ Libre de Bruxelles (CEBEA),
where the animal experiments were carried out.
Cells transfections
Primary fibroblasts from both healthy controls and FRDA
patients were plated at a concentration of 3610
5 well in antibiotic-
free DMEM 24 hours before the experiment. One hour before the
transfection, cells were growth in OPTI-MEMH (Gibco). For each
transfection a mix containing 1 mg of either the Ppargc1a ((h) sc-
38884; Santa Cruz Biotechnology) or control siRNA fluoresceine-
conjugated (sc-37007; Santa Cruz Biotechnology) and Lipofecta-
mine RNAiMAX (Invitrogen) in OPTI-MEMH was prepared.
Cells were incubated with the mix for 24 hours at 37uCi n
presence of CO2. Than complete DMEM was added and cells
were growth in normal conditions for 72 hours before total RNA
and protein extractions. The efficient of the transfection was
monitored by fluorescence microscopy for the fluoresceine-
conjugated siRNA and RT-PCR for the Ppargc1 siRNA.
Real-time quantitative PCR
Total mRNA from primary fibroblasts and SKNBE cells was
extracted using the RNeasy mini kit (Qiagen) according to the
manufacture’s protocol. Mice’s tissues were homogenized and
total RNA was extracted using the Qiazol reagent and the RNeasy
lipid tissues kit (Qiagen) according to the protocol. After a DNAse
treatment (RNAse-Free DNAse set, Qiagen), one microgram of
total mRNA from cells and tissues was reverse-transcribed with the
QuantiTect Reverse Transcription Kit (Qiagen). Approximately
100 ng of cDNA were amplified by Real-Time PCR using the
Power SYBRH Green Master mix (Applied Biosystems, Foster
City, CA). All the samples were run in triplicate using a 7500 Real
Time PCR system (Applied Biosystems, Foster City, CA). Post
assay analysis was performed using the SDS software, version 2.3
(Applied Biosystems, CA). qPCR primers are listed below: Human
(PPARGC1A: Qiagen (QT00095578); FXN: forward 59-CAGAG-
GAAACGCTGGACTCT-39, reverse 59-AGCCAGATTTGCT-
TGTTTGG-39; MnSOD: Qiagen (QT01008693); Act-b: forward
59-AGAAAATCTTGGCACCACACC-39, reverse 59-AACGG-
CAGAAGAGAGAACCA-39; GAPDH: forward 59- TGCAC-
CACCAACTGCTTAGC -39, reverse 59- GGCATGGACT-
GTGGTCATGAG -39); Mouse (Ppargc1a: Qiagen (QT00156
303); fxn: forward: 59-CCTGGCCGAGTTCTTTGAA-39, re-
verse: 59-GCCAGATTTGCTTGTTTGG-39; sod2: Qiagen
(QT00161707); act-b: forward: AACCGTGAAAAGATGACC-
CAGAT; reverse: 59-GCCTGGATGGCTACGTACATG-39;
rer1: forward: 59-CCACCTAAACCTTTTCATTGCG-39, re-
verse: 59-TTTGTAGCTGCGTGCCAAAAT-39). All the results
for both human and animal experiments have been normalized
using b-actin as reference gene. GAPDH for human samples and
rer1 for mouse samples have been additionally tested, in several
cases, to confirm the results. Quantitative Real-Time PCR
analyses were carried out using the 2(-Delta Delta C(T)) method
(2-DDCt).
Western blot
For total proteins extraction, fibroblasts and SKNBE cells were
lysed in a buffer containing 10 mM Tris (pH 7.4), 150 mM
NaCl, 1 mM EDTA (pH 8.0), 1% Triton X-100, 1 mM
phenylmethylsulfonyl fluoride and 10 mg/ml of leupeptin/apro-
tinin for 30 minutes on ice. The lysate was sonicated and the
concentration was determined using a Bradford assay. 100 mg of
total protein were used for the analysis. The running conditions
included a 10 min incubation at 10 mA (Volt and Watt at
maximum) and then a step at 25 mA for 60–90 min. For blotting,
a nitrocellulose membrane was used. Blotting was conducted at
10 W and 250 V (250 mA per gel) for 60 min. After blocking in
5% milk, the membrane was incubated with the primary
antibody (Frataxin, 1:5000; Chemicon; pgc1a, 1:1000; Cell
Signaling; SOD2, 1:1000 and b-actin, 1:10000; Sigma Aldrich)
lasted overnight at 4uC. After the incubation, the blot was washed
and a peroxidase conjugated secondary antibody was incubated
(goat anti mouse or anti rabbit HRP, 1:10,000; Jackson
ImmunoResearch, West Grove, PA) for 1 hr at room tempera-
ture. Finally, the blot was washed and processed for chemolu-
minescent detection. We quantified the relative intensities of each
signal using the Image J Software and normalized the values to
the intensity of Actin.
Statistical analyses
Statistical analyses were performed using the Sigma Stat
program (SigmaStat). The Shapiro-Wilk test was used to
determine whether the data were normally distributed, and then
statistical significance was calculated using the one sample T-test.
Differences with p values less than 0.05 (*p,0.05), less then 0.01
(**p,0.001) and less than 0.001 (***p,0.001) were considered to
be significant.
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Figure S1 Representative digital images of primary fibroblasts
from healthy controls and two FRDA patients at basal conditions.
Cells nuclei are in Blue (DAPI) and mitochondrial O2- production
are in red (MitoSox). Merge is obtained by overlapping the two
stain. B. Using digital image processing, the MitoSOX fluores-
cence intensity mean per image was calculated, averaged over
three fields of view per experiment, and then averaged over three
independent experiments. Data were normalized to static controls
MitoSOX fluorescence. (n=3, **p,0.01, *p,0.05; Mean +/2
SEM) for all the experiments.
Found at: doi:10.1371/journal.pone.0010025.s001 (1.05 MB TIF)
Methods S1 Supplementary methods: Fluorescent detection of
mitochondrial superoxide.
Found at: doi:10.1371/journal.pone.0010025.s002 (0.03 MB
DOC)
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